The severity of infectious pneumonia is influenced by various factors, including the type of pathogen, the patient's health status, age, and immune system condition. Pathogens such as bacteria, viruses, fungi, and mycoplasma can cause severe pneumonia that can be life-threatening. Antibiotic treatment for bacterial infections must be tailored to the specific sensitivities of different bacterial strains. However, the extensive use of antibiotics has led to the development of resistance through various mechanisms, rendering some pathogens insensitive to conventional treatments. The rise of multidrug-resistant bacteria and viruses poses a significant challenge, necessitating innovative approaches to overcome these resistance mechanisms and develop new therapies. Additionally, traditional antibiotics often lack specificity, affecting both harmful and beneficial bacterial communities.
For viral infections, including those caused by influenza and respiratory syncytial viruses, antiviral drugs work primarily by inhibiting viral replication, thereby reducing symptoms and shortening illness duration. In severe cases of lung infections, such as pneumonia or acute respiratory distress syndrome, novel immunomodulators can help regulate excessive inflammatory responses, reducing tissue damage. Vaccination remains a critical preventive measure, but traditional vaccine production faces challenges such as lengthy production cycles and stability issues.
Infectious lung diseases impose a significant global health burden, contributing to high morbidity, mortality, and healthcare costs. The ongoing COVID-19 pandemic underscores the urgent need for innovative strategies to combat respiratory pathogens and mitigate future pandemics. Advancements in biotechnology and nanotechnology offer promising solutions in the development and production of antibiotics and vaccines, potentially transforming the treatment landscape for infectious lung diseases.
This Research Topic aims to address the critical challenges posed by drug-resistant pathogens and the urgent need for innovative diagnostic and therapeutic approaches in infectious lung diseases. By fostering interdisciplinary collaboration and integrating emerging technologies such as artificial intelligence and synthetic biology, we seek to advance the development of targeted therapies, improve diagnostic sensitivity and specificity, and personalize treatment strategies. This Research Topic will highlight ongoing research efforts and facilitate the exchange of ideas to overcome existing challenges and address unmet clinical needs in combating respiratory infections.
We invite submissions of original research, reviews, mini-reviews, opinions, and perspectives on the following subjects:
o New vaccine developments for viral pneumonia, including influenza A/B, COVID-19, adenovirus, etc.
o Molecular imaging nanoprobes for elucidating the molecular mechanisms of pulmonary infections.
o Smart nanomaterials designed for precise drug delivery or release targeted at pulmonary infections.
o Functional nanomaterials with antiviral, antibacterial, and anti-mycoplasma properties.
Keywords:
theragnostic, pulmonary infection, nanotechnology
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
The severity of infectious pneumonia is influenced by various factors, including the type of pathogen, the patient's health status, age, and immune system condition. Pathogens such as bacteria, viruses, fungi, and mycoplasma can cause severe pneumonia that can be life-threatening. Antibiotic treatment for bacterial infections must be tailored to the specific sensitivities of different bacterial strains. However, the extensive use of antibiotics has led to the development of resistance through various mechanisms, rendering some pathogens insensitive to conventional treatments. The rise of multidrug-resistant bacteria and viruses poses a significant challenge, necessitating innovative approaches to overcome these resistance mechanisms and develop new therapies. Additionally, traditional antibiotics often lack specificity, affecting both harmful and beneficial bacterial communities.
For viral infections, including those caused by influenza and respiratory syncytial viruses, antiviral drugs work primarily by inhibiting viral replication, thereby reducing symptoms and shortening illness duration. In severe cases of lung infections, such as pneumonia or acute respiratory distress syndrome, novel immunomodulators can help regulate excessive inflammatory responses, reducing tissue damage. Vaccination remains a critical preventive measure, but traditional vaccine production faces challenges such as lengthy production cycles and stability issues.
Infectious lung diseases impose a significant global health burden, contributing to high morbidity, mortality, and healthcare costs. The ongoing COVID-19 pandemic underscores the urgent need for innovative strategies to combat respiratory pathogens and mitigate future pandemics. Advancements in biotechnology and nanotechnology offer promising solutions in the development and production of antibiotics and vaccines, potentially transforming the treatment landscape for infectious lung diseases.
This Research Topic aims to address the critical challenges posed by drug-resistant pathogens and the urgent need for innovative diagnostic and therapeutic approaches in infectious lung diseases. By fostering interdisciplinary collaboration and integrating emerging technologies such as artificial intelligence and synthetic biology, we seek to advance the development of targeted therapies, improve diagnostic sensitivity and specificity, and personalize treatment strategies. This Research Topic will highlight ongoing research efforts and facilitate the exchange of ideas to overcome existing challenges and address unmet clinical needs in combating respiratory infections.
We invite submissions of original research, reviews, mini-reviews, opinions, and perspectives on the following subjects:
o New vaccine developments for viral pneumonia, including influenza A/B, COVID-19, adenovirus, etc.
o Molecular imaging nanoprobes for elucidating the molecular mechanisms of pulmonary infections.
o Smart nanomaterials designed for precise drug delivery or release targeted at pulmonary infections.
o Functional nanomaterials with antiviral, antibacterial, and anti-mycoplasma properties.
Keywords:
theragnostic, pulmonary infection, nanotechnology
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.